# ISLHD CANCER CLINICAL TRIALS

## Illawarra Cancer Care Centre May 2024

### ISLHD CANCER CLINICAL TRIALS UNIT

Illawarra Cancer Care Centre Wollongong Hospital

Loftus Street Wollongong NSW 2500

> Ph: 02 4253 4384 Fax: 02 4222 5085

Email: ISLHD-CancerClinicalTrials@health. nsw.gov.au The Illawarra Shoalhaven Local Health District (ISLHD) Cancer Clinical Trials Unit has a specialist team of doctors, nurses, radiation therapists and allied health professionals supporting a comprehensive suite of clinical trials for our local community. We are based at Wollongong and Shoalhaven District Memorial Hospitals in the Illawarra Cancer Care Centre and Shoalhaven Cancer Care Centre.


Clinical trials contribute to evidence based practice, knowledge development and improved patient care. They provide our patients the opportunity to access novel and potentially efficacious treatment for their cancer close to home.

We currently have trials open for patients with:

- Breast cancer
- Colorectal cancer
- Lung cancer
- Pancreatic cancer
- Gynaecological neoplasms
- Prostate cancer
- Skin cancer

### **REFERRAL OR CONSULTATION**

To discuss your patient with an ISLHD Oncology Trials Clinician, please phone the Illawarra Cancer Care Centre on 02 4222 5200



#### Scan the QR Code for more information including eligibility criteria

Breast EXPERT: A randomised Phase III trial of adjuvant radia-Dr Fox tion therapy versus observation following breast conserv-Jo Boynton ing surgery and endocrine therapy in patients with luminal A early breast cancer.

> **TUGETHER:** A phase II, two-arm non-comparative, multi- Dr Kasherman centre study of tucatinib (ONT-380), pembrolizumab (MK-Tia Summer-3475) and trastuzumab in patients with pre-treated adside vanced HER2-positive breast cancer.

CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease. \*\*Opening soon\*\*

**OXTOX:** Can oxaliplatin neurotoxicity be reduced with GI/Biliary ibudilast in people with metastatic colorectal cancer - a phase II randomised study.

> **Neo-IMPACT:** A Phase 2 study to evaluate the feasibility and safety of combining modified Folfirinox (mFolfirinox) with durvalumab (MEDI4736) in patients with resectable or borderline resectable pancreatic adenocarcinoma.

- GU NINJA: Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation for patients with intermediate or low-high risk prostate cancer.
- Skin **C-POST:** A randomised, placebo-controlled, double-blind A/Prof Brungs study of adjuvant cemiplimab versus placebo after sur-Angela Muir gery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma.

**Prof Chantrill** Tia Summerside

Tia Summer-

side

**Prof Chantrill** Tia Summerside

**Prof Miller** Elise Cardoso





Page 2 of 4







SKB264: A multicenter, open-label, phase 2, basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with select- ed solid tumors. **Cohorts B only** (limited spots remaining)	Dr Kasherman Tia Summer- side	
<b>CIBI129A101:</b> A Phase 1/2 Study of IBI129 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumors. **Opening soon**	Dr Brungs TBC	
<b>MODERN-LUNG:</b> Phase 2 Study of a moderately hypofractionated schedule of chemoradiation followed by immunotherapy for unresectable locally advanced non-small cell lung cancer.	Dr Gandhida- san Tia Summer- side	
<b>177Lu-RAD204:</b> Phase 0/I Study of the Safety and Tol- erability of 177Lu-RAD204, a Lutetium-177 Radio- labelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients with Metastatic Non- small Cell Lung Cancer. **Opening soon**	A/Prof Brungs TBC	
		120.00

Dr Kasherman Angela Muir



Scan the QR Code for more information including eligibility criteria

**PARAGON2:** Phase II basket study of an ARomatase Gynae inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic Gynaecological Neoplasms. \*\*Cohorts A, B, D, E, F (limited spots) only\*\*

> **ARTISTRY-7:** A Phase 3, Multicenter, Open-Label, Ran- Dr Kasherman domized Study of Nemvaleukin Alfa in Combination with Tia Summer-Pembrolizumab Versus Investigator's Choice Chemoside therapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. \*\*Arms 1 and 4 only\*\*

Solid S Tumours s С e \*

Lung

### ISLHD Cancer Clinical Trials \*\*CURRENTLY OPEN FOR RECRUITMENT\*\*

For further information regarding these trials at the Illawarra Cancer Care Centre you may also contact the dedicated trial coordinator as listed or email <u>ISLHD-OncologyTrials</u> @health.nsw.gov.au

Trial Coordinator	Availability	Contact details
Kim Bate (Team Leader-Oncology)	Mon-Fri	Kim.Bate@health.nsw.gov.au
Tia Summerside	Mon-Fri	02 4253 4935
Yi-Shun Chiu	Mon-Fri	YiShun.Chiu@health.nsw.gov.au
Vaniesa Boneham	Mon-Fri	02 4222 5738
Victoria Cosatto	Mon-Fri	Victoria.Cosatto@health.nsw.gov.au
Angela Muir	Mon-Thurs	02 4222 5229
Elise Cardoso	Mon-Thurs	Elise.Cardoso@health.nsw.gov.au
Jo Boynton	Tues-Wed	02 4222 5739

